Alkem Laboratories announced its standalone and consolidated financial results for the third quarter ended December 31, 2025 (Q3 FY26). Total Revenue from Operations grew by 10.7% YoY to ₹37,368 Million, with EBITDA growing 9.0% YoY to ₹8,280 Million (Margin 22.2%). The Board also declared an Interim Dividend of ₹43 per share. The company also highlighted a strategic term sheet for acquiring a majority stake in Swiss cardiac implant firm Occlutech.
Q3 FY26 Financial Highlights Summary
Alkem Laboratories announced robust financial results for the third quarter ended December 31, 2025 (Q3 FY26). The Board of Directors, in their meeting on February 13, 2026, approved the unaudited financial results and declared an interim dividend.
Key consolidated financial metrics for Q3 FY26 showed significant growth:
- Total Revenue from Operations stood at ₹37,368 Million, marking a 10.7% YoY growth.
- EBITDA was ₹8,280 Million, resulting in a 22.2% margin, reflecting a 9.0% YoY growth.
- Profit After Tax (PAT, after NCI) was ₹6,360 Million, with a margin of 17.0%, showing a 1.6% YoY growth.
- Earnings Per Share (EPS) for continuing operations was ₹53.19 (Basic/Diluted).
Interim Dividend Declaration
The Board declared an Interim Dividend of ₹43 (Rupees forty-three only) per equity share on the face value of ₹2/- per share for FY 2025-2026. The record date for this dividend payment is set as Friday, February 20, 2026, with payment commencing on or from March 6, 2026.
Geographic Performance Breakdown
The growth was strong across both domestic and international segments:
- Domestic Business: Sales were ₹24,959 Million, growing 5.5% YoY. Domestic sales contributed 67.2% to total revenue. The company continued to outperform the Indian Pharmaceutical Market (IPM) in key therapy areas, notably outpacing IPM growth by 80 bps in the acute segment.
- International Business: Sales reached ₹12,157 Million, showing a sharp 26.6% YoY growth. US sales contributed 20.3% of total sales, growing 18.8% YoY to ₹7,533 Million, driven by strong traction in new launches. Non-US business grew by 41.6% YoY.
Strategic Business Update: Occlutech Acquisition
Alkem Laboratories also announced the execution of a binding term sheet to acquire a majority stake in Occlutech Holding AG, a Swiss-based global medical devices company specializing in minimally invasive cardiac implants. This strategic move is aimed at establishing a global footprint in the medical devices sector, with the subsidiary Alkem MedTech Pvt Ltd executing the transaction. Management views this as a significant lever for expansion into cardiovascular and orthopedics.
Exceptional Items Noted
The financial results for Q3 FY26 include an exceptional item of ₹527.9 Million classified on a preliminary basis, related to the incremental impact analysis following the notification of four new Labour Codes by the Government of India, effective November 21, 2025.
Regulatory and Operational Confidence
The company maintains strong regulatory compliance across its facilities, with several sites showing “No observation” status from recent inspections, including API facilities in Ankleshwar and Mandva, and the California (USA) API facility.
Company Snapshot (FY25 reference)
As a reference point from the previous fiscal year (FY25), Alkem held the #3 Rank in Prescriptions nationally and was the #5 Rank by value in the IPM. The company is also a leading player in the Trade Generics segment.
Source: BSE
